Concepedia

Author

Seigo Katakura

Yokohama City UniversityORCID

Also Known As

Katakura, S, S Katakura, S. KATAKURA, S. Katakura, SEIGO KATAKURA, SHIGEKI KATAKURA, Seigo Katakura, Shigeki KATAKURA

69

Publications

289

Citations

10

H-Index

10

Concepts

All Affiliations

Yokohama City UniversityYokohama City University Medical CenterYanbian UniversityYanbian University Hospital
SK

About

Seigo Katakura is an author at Yokohama City University specializing in medicine, antimicrobial resistance, and drug resistance.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

26

2

Immunology

1

1

15

3

Pathology

1

1

15

4

Drug Resistance

1

1

11

5

Tuberculosis

1

1

15

Seigo Katakura

×

8

Publications

113

Citations

8

H-Index

YearCitations

Selective insufficiency of IFN‐γ secretion in patients with hyper‐IgE syndrome

Ryuta Ito, Masaaki Mori, Seigo Katakura,

Allergy

2003

20

<scp>MicroRNA</scp>‐200b is a potential biomarker of the expression of <scp>PD‐L1</scp> in patients with lung cancer

Seigo Katakura, Nobuaki Kobayashi, Hisashi Hashimoto,

Thoracic Cancer

2020

20

Identification of Biomarkers for Non–small-cell Lung Cancer Patients Treated With an Immune Checkpoint Inhibitor

Sousuke Kubo, Nobuaki Kobayashi, Kohei Somekawa,

Anticancer Research

2020

17

Identification of a novel biomarker based on lymphocyte count, albumin level, and TBAg/PHA ratio for differentiation between active and latent tuberculosis infection in Japan

Seigo Katakura, Nobuaki Kobayashi, Hisashi Hashimoto,

Tuberculosis

2020

15

Staphylococcal scalded skin syndrome caused by exfoliative toxin B-producing methicillin-resistant

Shumpei Yokota, Tomoyuki Imagawa, Seigo Katakura,

European Journal of Pediatrics

1996

11

[A case of macrophage activation syndrome developed with systemic juvenile rheumatoid arthritis].

Tomoyuki Imagawa, Seigo Katakura, Mari Mori,

PubMed

1997

10

T‐cell response to phytohemagglutinin in the interferon‐γ release assay as a potential biomarker for the response to immune checkpoint inhibitors in patients with non‐small cell lung cancer

Chisato Kamimaki, Nobuaki Kobayashi, Momo Hirata,

Thoracic Cancer

2021

10

First-line immune checkpoint inhibitors alone or in combination with chemotherapy in real-life elderly patients with advanced non-small cell lung cancer (NEJ057).

Mao Uematsu, Yoko Tsukita, Takehiro Tozuka,

Journal of Clinical Oncology

2023

10

Page 1